# Vanita Noronha

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vanita-noronha/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,735 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 38 |
| i10-index | 140 |
| Last Known Institution | Homi Bhabha National Institute |
| OpenAlex ID | https://openalex.org/A5027531002 |
| ORCID iD | 0000-0002-0191-2744 |
| Works | 652 |

## Researcher papers

- [Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update](https://scholariq.org/papers/practical-assessment-and-management-of-vulnerabilities-in-older-patients-2/)
- [Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer](https://scholariq.org/papers/gefitinib-versus-gefitinib-plus-pemetrexed-and-carboplatin-chemotherapy-in-i/)
- [Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial](https://scholariq.org/papers/once-a-week-versus-once-every-3-weeks-cisplatin-chemoradiation-for-locally/)
- [Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial](https://scholariq.org/papers/prostate-only-versus-whole-pelvic-radiation-therapy-in-high-risk-and-very-high/)
- [Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study](https://scholariq.org/papers/low-dose-immunotherapy-in-head-and-neck-cancer-a-randomized-study/)
- [Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience](https://scholariq.org/papers/epidemiology-of-lung-cancer-in-india-focus-on-the-differences-between-non/)
- [Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data](https://scholariq.org/papers/weekly-low-dose-versus-three-weekly-high-dose-cisplatin-for-concurrent/)
- [Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers](https://scholariq.org/papers/neoadjuvant-chemotherapy-followed-by-surgery-in-very-locally-advanced/)
- [Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations](https://scholariq.org/papers/actionable-activating-oncogenic-erbb2-her2-transmembrane-and-juxtamembrane/)
- [Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity](https://scholariq.org/papers/frequency-of-egfr-mutations-in-907-lung-adenocarcioma-patients-of-indian/)
- [Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients](https://scholariq.org/papers/repeat-biopsy-in-epidermal-growth-factor-receptor-mutation-positive-nonsmall/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Oral health in cancer treatment](https://scholariq.org/topics/oral-health-in-cancer-treatment/)

## Researcher university

- [Homi Bhabha National Institute](https://scholariq.org/institutions/homi-bhabha-national-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.